Medidata Announces Rave Lite to Support Growth in Early and Late-Stage Clinical Trials

New offering leverages Medidata Rave EDC, making the world’s leading electronic clinical data capture available to market segments historically lacking access to the cutting-edge technology

NEW YORK--Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Medidata Rave Lite, an extension of the company’s gold-standard clinical research software, Medidata Rave EDC, designed explicitly for Phase I and Phase IV studies. Regardless of company size, therapeutic focus, or pipeline, Rave Lite provides efficient electronic clinical data capture (EDC), management, and analysis solutions with a tailored pricing model.

While EDC is a fundamental building block of clinical trials, technology fragmentation across phases leads to integration challenges and delays in startup times. In particular, the lack of access to innovative technology disproportionately affects early- and late-stage studies. Having addressed these challenges in over 34,000 trials, Medidata is now offering superior options for Phase I and Phase IV studies with Rave Lite.

With Medidata Designer integration, study builders can design Phase I and Phase IV trials with speed and precision, and with the continued use of AI, potential study misconfigurations are reduced while securing data integrity. Thus, Rave Lite offers a consistent experience without sacrificing the advanced power of Rave EDC.

“Rave Lite addresses a critical need in the market for early and late-stage trials, offering a streamlined solution built on our trusted Rave EDC platform,” said Tom Doyle, chief technology officer, Medidata. “By giving our customers the ability to use one EDC ubiquitously across all phases, customers gain the flexibility to scale their studies while maintaining the high standards that have long defined Medidata’s solutions.”

Rave EDC was recently recognized as the leading provider by Everest Group‘s first-ever PEAK Matrix® for its effectiveness in simplifying clinical trials for sponsors and CROs while ensuring data quality and integrity.

Medidata will showcase Rave Lite at NEXT New York, the premier clinical trials conference hosted by the company, in New York City on November 13 and 14. The solution will be made available to customers in early 2025. For more information on how Rave Lite can benefit research, click here.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com